Lutetium‐177 DOTATATE for the Treatment of Esthesioneuroblastoma: A Case Report
Case Reports in Oncological Medicine · 2025-01 · 2025 (1)
DOI: 10.1155/crom/5563379 ↗Kurz gefasst
Fallbericht in der Zeitschrift Case Reports in Oncological Medicine, online erschienen am 06.11.2025. Verfasst von Vaneza Avila-Rodriguez und 9 weiteren Autor:innen. Beteiligte Einrichtung: Neuro-Oncology Unit, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC), Bogotá, Colombia. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Esthesioneuroblastoma (ENB), also known as olfactory neuroblastoma, is a rare neuroendocrine malignancy arising from the olfactory neuroepithelium. It exhibits a wide range of biological behaviors, from indolent to highly aggressive disease, often requiring a multimodal treatment approach involving surgical resection, radiotherapy, and chemotherapy, though outcomes remain variable. The overexpression of somatostatin receptors (SSTRs), particularly SSTR2, has led to the exploration of peptide receptor radionuclide therapy (PRRT) with lutetium‐177 DOTATATE (Lu‐177) as a targeted option in refractory cases. We present the case of a 64‐year‐old woman with recurrent, metastatic ENB, Kadish Stage D (T2N0M0G2). After undergoing surgical resection, intensity‐modulated radiotherapy (IMRT), and systemic chemotherapy (cisplatin/etoposide), the patient experienced disease progression, prompting the initiation of targeted therapy with sunitinib. Given high SSTR expression detected on Gallium‐68 PET imaging, four cycles of PRRT with Lu‐177 DOTATATE were introduced with adverse effects (Grade 1 fatigue, nausea, leukopenia, anemia, and thrombocytopenia). While initial tumor regression was observed, subsequent progression necessitated further stereotactic body radiotherapy (SBRT) and temozolomide. This case highlights the therapeutic potential of PRRT with Lu‐177 DOTATATE in treating refractory SSTR‐expressing ENB. A multidisciplinary approach that integrates surgery, radiotherapy, systemic therapy, and theragnostic strategies remains essential to optimizing patient outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Neuro-Oncology Unit, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC), Bogotá, Colombia.
- GIGA/TERA Research Groups, CTIC/Universidad El Bosque, Bogotá, Colombia.
- University of North Carolina at Chapel Hill, School of Global Public Health, Chapel Hill, North Carolina, USA.
- Radiotherapy Oncology Unit, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC), Bogotá, Colombia.
- Foundation for Clinical and Applied Cancer Research-FICMAC, Bogotá, Colombia.
ORCID-Profile: Vaneza Avila-Rodriguez, Nicolle Wagner-Gutiérrez, Javier Jacobo, Alejandro Gonzalez, Ivan Bobadilla, Andrés F Cardona
Zitieren
APA
Avila-Rodriguez, V., Wagner-Gutiérrez, N., Jacobo, J., Pineda, D., Gonzalez, A., Aristizabal, J., Bobadilla, I., Sánchez, N., Zuluaga, J. A., & Cardona, A. F. (2025). Lutetium‐177 DOTATATE for the Treatment of Esthesioneuroblastoma: A Case Report. Case Reports in Oncological Medicine, 2025(1). https://doi.org/10.1155/crom/5563379
Vancouver
Avila-Rodriguez V, Wagner-Gutiérrez N, Jacobo J, Pineda D, Gonzalez A, Aristizabal J, et al. Lutetium‐177 DOTATATE for the Treatment of Esthesioneuroblastoma: A Case Report. Case Reports in Oncological Medicine. 2025;2025(1). doi:10.1155/crom/5563379
BibTeX
@article{AvilaRodriguez2025,
author = {Avila-Rodriguez, Vaneza and Wagner-Gutiérrez, Nicolle and Jacobo, Javier and Pineda, Diego and Gonzalez, Alejandro and Aristizabal, Jorge and Bobadilla, Ivan and Sánchez, Natalia and Zuluaga, Jairo A and Cardona, Andrés F},
title = {Lutetium‐177 DOTATATE for the Treatment of Esthesioneuroblastoma: A Case Report},
journal = {Case Reports in Oncological Medicine},
year = {2025},
volume = {2025},
number = {1},
doi = {10.1155/crom/5563379}
}
EUVIMED